ES2062051T3 - Derivados heterociclicos. - Google Patents

Derivados heterociclicos.

Info

Publication number
ES2062051T3
ES2062051T3 ES89313384T ES89313384T ES2062051T3 ES 2062051 T3 ES2062051 T3 ES 2062051T3 ES 89313384 T ES89313384 T ES 89313384T ES 89313384 T ES89313384 T ES 89313384T ES 2062051 T3 ES2062051 T3 ES 2062051T3
Authority
ES
Spain
Prior art keywords
alkylene
hetero
alkynyl
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89313384T
Other languages
English (en)
Inventor
Philip Neil Edwards
Jean-Marc Marie Mauri Girodeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Imperial Chemical Industries Ltd
Original Assignee
ICI Pharma SA
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICI Pharma SA, Imperial Chemical Industries Ltd filed Critical ICI Pharma SA
Application granted granted Critical
Publication of ES2062051T3 publication Critical patent/ES2062051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

EL INVENTO CONCIERNE A UN DERIVADO HETEROCICLICO DE LA FORMULA I, EN DONDE AR1 ES FENIL O NAFTIL OPCIONALMENTE SUSTITUIDO; A1 ES ALQUILENO (C1-6), ALQUENILENO (C3-6), ALQUINILENO (C3-6) O ALQUILENO (C3-6)CICLO; AR2 ES FENILENO OPCIONALMENTE SUSTITUIDO, O UNA PARTE HETEROCICLENO DE 6 MIEMBROS QUE CONTIENEN MAS DE TRES NITROGENOS; R1 ES HIDROGENO, ALQUIL (C1-6), ALQUENIL (C3-6), ALQUINIL (C3-6), ALQUIL (C1-4)CIANO O ALCANOIL (C2-4), O BENZOIL OPCIONALMENTE SUSTITUIDO; Y R2 Y R3 JUNTOS FORMAN UN GRUPO DE LA FORMULA -A2-X-A3- EN DONDE CADA A2 Y A3 SON ALQUILENO (C1-4) Y X ES OXI, TIO, SULFINIL, SULFONIL O IMINO; O UNA SAL DE ELLO ACEPTABLE FARMACEUTICAMENTE. LOS COMPONENTES DEL INVENTO SON INHIBIDORES DE LA ENZIMA LIPOXIGENASA-5.
ES89313384T 1988-12-23 1989-12-20 Derivados heterociclicos. Expired - Lifetime ES2062051T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP88403313 1988-12-23
EP89401491 1989-05-31

Publications (1)

Publication Number Publication Date
ES2062051T3 true ES2062051T3 (es) 1994-12-16

Family

ID=26118235

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89313384T Expired - Lifetime ES2062051T3 (es) 1988-12-23 1989-12-20 Derivados heterociclicos.

Country Status (16)

Country Link
US (1) US5098930A (es)
EP (1) EP0375404B1 (es)
JP (1) JPH03135975A (es)
AU (1) AU624663B2 (es)
CA (1) CA2006377A1 (es)
DE (1) DE68913022T2 (es)
DK (1) DK654589A (es)
ES (1) ES2062051T3 (es)
FI (1) FI896014A0 (es)
GB (1) GB8926981D0 (es)
HU (1) HUT52767A (es)
IE (1) IE63047B1 (es)
IL (1) IL92556A (es)
NO (1) NO895086L (es)
NZ (1) NZ231665A (es)
PT (1) PT92699B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64358B1 (en) * 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
AU637500B2 (en) * 1990-06-21 1993-05-27 Zeneca Limited Bicyclic heterocyclic compounds
EP0462830B1 (en) * 1990-06-21 1995-10-18 Zeneca Limited Cyclic ether derivatives
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
US5272173A (en) * 1990-11-28 1993-12-21 Imperial Chemical Industries Plc 5-lipoxygenase inhibitors
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
CA2058254A1 (en) * 1991-01-15 1992-07-16 John Francis Kingston Benzodioxole derivatives
US5258399A (en) * 1991-01-17 1993-11-02 Imperial Chemical Industries Plc Sulphonamide derivatives
IL100483A0 (en) * 1991-01-17 1992-09-06 Ici Plc Sulphonamide derivatives
US5281720A (en) * 1991-02-28 1994-01-25 Merck Frosst Canada, Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
EP0501578A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
US5227399A (en) * 1991-02-28 1993-07-13 Merck Frosst Canada, Inc. Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
EP0501579A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalene lactones as inhibitors of leukotriene biosynthesis
EP0505122A1 (en) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, alpha-dialkylbenzyl derivatives
EP0532239B1 (en) * 1991-09-10 1995-12-13 Zeneca Limited Benzenesulphonamide derivatives as 5-lipoxygenase inhibitors
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
GB9300894D0 (en) * 1992-02-07 1993-03-10 Zeneca Ltd Oxime derivatives
EP0555067A1 (en) * 1992-02-07 1993-08-11 Zeneca Limited Hydroxylamine derivatives as 5-lipoxygenase inhibitors
CA2094465A1 (en) * 1992-04-23 1993-10-24 Pierre Andre Raymond Bruneau Cycloalkane derivatives
CA2095005A1 (en) * 1992-05-12 1993-11-13 Philip Neil Edwards Hydroxylamine derivatives
EP0570197B1 (en) * 1992-05-12 1995-12-13 Zeneca Limited Hydroxylamine derivatives
CA2095006A1 (en) * 1992-05-12 1993-11-13 Philip Neil Edwards Oxime derivatives
EP0570196B1 (en) * 1992-05-12 1996-03-06 Zeneca Limited Oxime derivatives
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US5426109A (en) * 1992-08-27 1995-06-20 Merck Frosst Canada, Inc. Phenylnaphthalene hydroxy acids
US5350744A (en) * 1992-08-27 1994-09-27 Merck Frosst Canada, Inc. Phenylnaphthalene lactones as inhibitors of leukotriene biosynthesis
US5428060A (en) * 1992-08-27 1995-06-27 Merck Frosst Canada, Inc. Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
AU4444393A (en) * 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
GR920100426A (el) * 1992-10-08 1994-06-30 Ici Pharma Παράγωγα βενζολοσουλφοναμιδίου.
IL109254A (en) * 1993-04-29 1999-03-12 Zeneca Ltd History of the tetrahydropyran and tetrahydropuran site preparation and pharmaceutical preparations containing them
BR9406822A (pt) * 1993-06-14 1996-03-26 Pfizer Inibidores imidazol de lipoxigenase
IL110280A0 (en) * 1993-07-27 1994-10-21 Zeneca Ltd Thiazole derivatives
ZA945250B (en) * 1993-07-27 1995-01-27 Zeneca Ltd Thiazole derivatives
EP0636624A1 (en) * 1993-07-27 1995-02-01 Zeneca Limited Thiazole derivatives as lipoxygenase inhibitors
US5446062A (en) * 1993-11-12 1995-08-29 Abbott Laboratories ((4-alkoxypyran-4-yl) substituted) ether, arylalkyl-, arylalkenyl-, and arylalkynyl)urea inhibitors of 5-lipoxygenase
US5407959A (en) * 1993-11-12 1995-04-18 Abbott Laboratories (Trans-1,4-dialkoxycyclohexyl) substituted arylalkylaryl-arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
ES2119377T3 (es) * 1994-03-28 1998-10-01 Pfizer Derivados bencisotiazoles inhibidores de la biosintesis de la 5-lipoxigenasa.
WO1995030669A1 (en) * 1994-05-06 1995-11-16 Zeneca Limited Ether derivatives and pharmaceutical compositions containing them
DE59813344D1 (de) 1997-11-03 2006-04-06 Aventis Res & Tech Gmbh & Co Fluorierte naphthalin-derivate und ihre verwendung in flüssigkristallinen mischungen
CA2269561C (en) * 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
AU1820002A (en) * 2000-10-03 2002-04-15 Syngenta Participations Ag Phenylpropynyloxypyridine herbicides
US6825221B2 (en) 2001-10-18 2004-11-30 Allergan, Inc. Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743737A (en) * 1970-05-21 1973-07-03 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperindinylcarbinol compositions
CA960676A (en) * 1970-05-21 1975-01-07 Smith Kline And French Canada Ltd. 3-sulfonamido-4-hydroxyphenyl-2-piperidinylcarbinols
US3661917A (en) * 1970-05-21 1972-05-09 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperidylcarbinols
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
GB8306512D0 (en) * 1983-03-09 1983-04-13 Ici Plc Heterocyclic compounds
NZ213986A (en) * 1984-10-30 1989-07-27 Usv Pharma Corp Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
FR2611714A2 (fr) * 1986-04-23 1988-09-09 Rhone Poulenc Agrochimie Composes a groupements triazole ou imidazole et tetrahydrofuran, utilisation de ceux-ci a titre de fongicides et procedes de preparation
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920133A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
EP0349062A1 (en) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Quinoline ether alkanoic acid
IE64358B1 (en) * 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles

Also Published As

Publication number Publication date
DK654589D0 (da) 1989-12-21
IL92556A (en) 1994-04-12
JPH03135975A (ja) 1991-06-10
DE68913022D1 (de) 1994-03-24
GB8926981D0 (en) 1990-01-17
DK654589A (da) 1990-06-24
IL92556A0 (en) 1990-08-31
AU624663B2 (en) 1992-06-18
IE893880L (en) 1990-06-23
EP0375404A3 (en) 1991-01-16
HUT52767A (en) 1990-08-28
NZ231665A (en) 1992-02-25
NO895086L (no) 1990-06-25
CA2006377A1 (en) 1990-06-23
DE68913022T2 (de) 1994-05-11
FI896014A0 (fi) 1989-12-15
PT92699B (pt) 1995-09-12
IE63047B1 (en) 1995-03-22
HU896626D0 (en) 1990-02-28
NO895086D0 (no) 1989-12-18
PT92699A (pt) 1990-06-29
EP0375404A2 (en) 1990-06-27
EP0375404B1 (en) 1994-02-09
US5098930A (en) 1992-03-24
AU4619889A (en) 1990-06-28

Similar Documents

Publication Publication Date Title
ES2062051T3 (es) Derivados heterociclicos.
ES2063149T3 (es) Derivados de eteres ciclicos.
ES2079576T3 (es) Derivados piranicos biciclicos y su uso como inhibidores de 5-lipoxigenasa.
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
ES2040276T3 (es) Derivados de la indolizina, procedimiento para su preparacion y composiciones que los contienen.
PE18095A1 (es) 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
RO82508B (ro) PROCEDEU PENTRU PREPARAREA UNOR DERIVATI DE 3-(1-PIPERIDINILACHIL)-4H-PIRIDO-(1,2-a)- PIRIMIDIN-4-ONA
ES2159758T3 (es) Nuevas n-aminoalquilfluorenocarboxamidas; una nueva clase de ligandos especificos a subtipos del receptor de la dopamina.
ES2192394T3 (es) Profarmacos de inhibidores de la bomba de protones.
ES2072952T3 (es) Pleuromutilinas.
ES2175834T3 (es) Nuevos analogos tretaciclicos de camptotecinam, sus procedimientos de preparacion, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ATE316799T1 (de) Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
ES2122275T3 (es) Derivados amidicos de la vitamina d.
CO5180556A1 (es) Derivados de la indolilpiperidina como agentes antihistaminicos y antialergicos
AR246289A1 (es) Composicion inhibidora de polimerizacion.
ES2062098T3 (es) Derivados de bencimidazol farmacologicamente activos.
NO170083C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aromatiske derivater
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2090143T3 (es) Acidos gem-difosfonicos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2036948B1 (es) Procedimiento de obtencion de compuestos derivados de piridina.
CO5180637A1 (es) Piradazinas sustituidas y piradazinas fusionadas con actividad inhibidora de angiogenesis
ES2057415T3 (es) Derivados biciclicos.
ES2037011T3 (es) Procedimiento para la preparacion de nuevos derivados de benzofuran-2-il-imidazol.
CO5180536A1 (es) Inhibidores de proteasas catepsina
MX9704435A (es) Compuestos de tiazolidinona y agente terapeutico o agente de prevencion para angina de pecho, que comprende los compuestos como un ingrediente activo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375404

Country of ref document: ES